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Role of body composition and metabolic proﬁle in
Barrett’s oesophagus and progression to cancer
Simona Di Caroa,*, Wui Hang Cheungb,d,*, Lucia Finic, Margaret G. Keanea, Belinda Theisa, Rehan Haidrya,
Laura Di Renzob,d, Antonino De Lorenzob,d, Laurence Lovata, Rachel L. Batterhamb,d and Matthew Banksa
Background and aims The aim of this study was to evaluate the risk for Barrett’s oesophagus (BE) on the basis of body
composition, metabolic pathways, adipokines and metabolic syndrome (MS), as well as their role in cancer progression.
Methods In patients with and without BE at gastroscopy, data on MS, BMI, waist/hip ratio for abdominal obesity (AO) and body
fat percentage by bioimpedance were obtained. Fasting plasma glucose, insulin, HbA1c, lipid, serum adiponectin and leptin
levels were measured. The homoeostasis model assessment (HOMA-IR) was used to estimate insulin resistance. Histological
ﬁndings for BE were correlated with the above parameters. Risk factors for BE identiﬁed using univariate analysis were entered
into a multivariate logistic regression analysis.
Results A total of 250 patients and 224 controls (F/M: 189/285, mean age 58.08± 15.51 years) were enroled. In the BE and
control groups, 39.6 versus 31.3% were overweight, 32 versus 22.8% were obese, 75.6 versus 51.3% had AO, and 28.1 versus
18.9% were metabolically obese, respectively. AO [odds ratio (OR) 3.08], increased body fat percentage (OR 2.29), and higher
BMI (overweight: OR 2.04; obese: OR 2.26) were signiﬁcantly associated with BE. A positive trend was found in Normal Weight
Obese Syndrome (OR 1.69). MS was associated with BE (overweight: OR 3.05; obese: OR 5.2; AO: OR 8.08). Insulin levels
(P=0.05) and HOMA-IR (P< 0.001) were higher in BE. AO was the only independent risk factor associated with BE (OR 1.65;
P=0.02) and high-grade dysplasia (OR 2.44) on multivariate analysis.
Conclusion AO was strongly associated with BE and dysplasia. BE was associated with MS and higher insulin/HOMA-IR,
suggesting the activation of speciﬁc metabolic pathways in patients with altered body composition. Eur J Gastroenterol Hepatol
28:251–260
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Introduction
Over the last few decades there has been a marked increase
in the incidence of oesophageal adenocarcinoma (OAC)
throughout North America and Europe at a rate exceeding
that for any other solid tumour [1].
The underlying reasons for this are unclear, although
gastro-oesophageal reﬂux, smoking and central adiposity
are risk factors [2]. Oesophageal cancer is now the sixth
most common cause of cancer-related death and accounts
for around 5% of all cancer-related deaths in the UK [3].
Early diagnosis can substantially improve survival in
OAC. Barrett’s oesophagus (BE) remains the strongest
recognized risk factor for OAC and, therefore, surveillance
endoscopic programmes have been endorsed to prevent
cancer progression in patients with BE [3,4]. In clinical
practice, the presence of dysplasia identiﬁes patients with
BE who require treatment [5,6].
In parallel to OAC, rates of obesity (deﬁned as
BMI>30 kg/m2) and type 2 diabetes (T2D) have risen to
epidemic proportions in the USA, Europe and Asia [7]. In
the UK, in 2010, 26.1% of adults were reported to be
obese, one of the highest rates in Europe, and 4.3% were
estimated to have T2D [8]. Although other factors such as
genetic predisposition may contribute to obesity, in gen-
eral, increased caloric intake and decreased physical
activity have been identiﬁed as primary causes for the
observed trends [1,9]. Literature suggests that visceral
abdominal fat is associated with an increased risk for T2D,
ischaemic heart disease and malignancies including colo-
rectal cancer [10,11].
Recent studies have clearly implicated chronic gastro-
oesophageal reﬂux disease (GERD) and several lifestyle
risk factors, including tobacco consumption, diet and
particularly obesity, as being associated with increased risk
for OAC, although the mechanism accounting for this link
is unclear [12]. Reports describing how obesity per se
predisposes individuals to GERD and BE through an
increase in abdominal pressure have yielded conﬂicting
results. A pathway from reﬂux to inﬂammation through
metaplasia and dysplasia is the dominant hypothesis [13].
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Abdominal fat is believed to play a crucial role in the
development of oesophageal diseases, not only through the
chronic increase in intra-abdominal pressure inducing
oesophageal acid exposure but also through the endocrine
function of the adipose mass, which represents an impor-
tant source of proinﬂammatory cytokines (interleukin-1β,
interleukin-6, tumour necrosis factor-α), leading to
increased levels of leptin and procoagulant factors and
reduced levels of protective adipokines (i.e. adiponectin)
[12–27].
BMI is a widely used measure of nutrition status and
adiposity and is correlated with the risk for T2D and
cardiovascular disease [28]. BMI, however, does not
account for BF distribution. Central (visceral or abdom-
inal) obesity, deﬁned by the waist/hip ratio (WHR), is
strongly correlated with insulin resistance and a greater
risk for obesity-related morbidity compared with overall
adiposity [29,30]. In particular, visceral obesity has been
associated with oesophageal and junctional adenocarci-
nomas [31]. Recently, a new category of individuals with a
higher risk of developing obesity-related diseases has been
identiﬁed. Females with normal weight (BMI <25.0 kg/m2)
but whose fat mass is greater than 30% of their total body
weight, localized typically in the abdomen, are considered
‘metabolically’ obese and affected by ‘Normal Weight
Obese Syndrome’ (NWOS) [32,33]. Recognizing and
managing metabolically obese normal weight individuals
is of major importance as they will beneﬁt from preventive
strategies.
Establishing an association between BE and obesity,
body composition, metabolic syndrome (MS) and meta-
bolic proﬁle characteristics, along with further under-
standing of causality, would provide opportunities for
intervention and prevention; this represents a crucial
public health issue, given the growing obesity epidemic
worldwide. The aim of our study was, therefore, to eval-
uate the association of obesity, body composition char-
acteristics, dysfunction of metabolic indices/pathways and
adipokines in patients with and without BE, and to
examine their potential role in the metaplasia, dysplasia,
cancer pathway in BE.
Patients and methods
This was a prospective single-centre case/control study con-
ducted at University College Hospital, London, UK (UCLH),
where subjects were enroled from May 2011 to May 2013.
This research was approved by an independent ethics com-
mittee, East Central London REC 1. Funding was secured by
application to the Clinical Research and Development
Committee Research Funding from The UCLH Charities
Fast Track Grant (Award number CDRC Reference: GCT/
2011/MB). Patients were invited to participate in the study
through letters when receiving their appointment for clini-
cally indicated oesophagogastroduodenoscopy (OGD).
Patients with known BE were recruited sequentially
from the Endoscopy Unit during the surveillance/ther-
apeutic OGD programme for BE (Fig. 1).
The control group was also recruited sequentially from
among patients booked to undergo an elective OGD for
any other indication and from among those who did not
have BE or OAC at endoscopy. If BE was newly diag-
nosed, patients were assigned to the case group.
The eligibility and exclusion criteria have been sum-
marized in Table 1.
Anthropometry, body composition analysis and metabolic
screening
After the patients signed the informed consent form,
details on demographics (age, sex and ethnicity), the pre-
sence of metabolic syndrome (hypertension, T2D and
dyslipidaemia) and current medications were recorded. In
addition, the required anthropometric measurements were
taken: waist and hip circumferences, using ﬂexible tape,
and height and weight measurements, using a study-
dedicated stadometer (Seca 213; Seca, Birmingham, UK)
and digital scale (Seca 813). Body composition was ana-
lysed through bioimpedance using QuadScan 4000
Bodystat (Bodystat Ltd, Douglas, Isle of Man, UK), a
multifrequency bioelectrical impedance analysis unit.
Venous blood sampling and metabolic pathways proﬁle
A fasting (8 h) blood sample (∼15ml in two heparinized
tubes) was taken for analysis. Initial parameters analysed
in the UCLH laboratory included plasma glucose, total
cholesterol and triglyceride, high-density lipoprotein,
insulin and HbA1c. A second heparinized blood sample
tube was taken to the Clinical Research Facility at UCLH
to be spun down to separate plasma from serum, which
was then stored in a − 80°C freezer. Subsequently, these
samples were analysed in the Laboratory of the Centre for
Obesity Research using Millipore ELISA kits (Human
Leptin ‘Dual Range’ ELISA and Human Adiponectin Elisa
Kit; Millipore, Feltham, UK) to determine serum leptin and
adiponectin levels. Each kit is sufﬁcient to run one 96-well
plate, measuring 38 samples in duplicate.
Patient classiﬁcation
Patients were classiﬁed according to BMI, abdominal obesity
(AO by WHR) and NWOS in women [32]. A BMI greater
than 30 kg/m2, and a WHR greater than 90 cm in men and
greater than 85 cm in women were deﬁned as obese or
abdominal (visceral) obesity (AO), respectively [34]. NWOS
was deﬁned as females with normal BMI but a total BF%
greater than 30% [34–36]. The presence of MS was assessed
using International Diabetes Federation criteria [37].
Insulin resistance (IR) was estimated on the basis of the
homoeostasis model assessment (HOMA), using the fol-
lowing formula: HOMA-IR=FPI×FPG/405, where FPI is
the fasting plasma insulin concentration (µIU/ml) and FPG
is fasting plasma glucose (mg/dl) [38]. Table 2 provides the
deﬁnitions used to classify patients based on MS, BMI and
body composition.
Endoscopy
BE was deﬁned according to British Society of
Gastroenterology guidelines [39].
During OGD, BE was classiﬁed on the basis of the
Prague C and M Endoscopic Criteria, and biopsies were
taken for histopathological reporting, in keeping with
standard clinical practice for BE [40]. Endoscopic treat-
ment was performed as clinically indicated. This also
applied to any individual in the control group who was
found to have BE. A deﬁnitive diagnosis of BE was
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conﬁrmed only after histopathological examination of the
biopsy. Long-segment BE was deﬁned as 3 cm or greater,
whereas short-segment BE was deﬁned as less than 3 cm.
Histopathological and Prague classiﬁcation of BEs were
based on the highest dysplasia or cancer score and the
maximum length, at any stage of treatment/surveillance.
All biopsies demonstrating dysplasia were reviewed by two
expert pathologists.
Statistics
The sample size was calculated to show the difference in
the proportion of participants who were obese, overweight
or metabolically obese in the BE group compared with the
control group.
The prevalence of BE in visceral obese patients is
around 40%, as previously reported, whereas the pre-
valence of BE is 1.6% in population-based analysis and
10% in patients with symptoms [41–43]. It is known that,
in England, the proportion of men classiﬁed as obese
increased from 13.2% in 1993 to 23.1% in 2005, and
from 16.4 to 24.8% among women during the same per-
iod. It is known that the risk of being overweight or obese
increases with age. About 28% of men and 27% of
women aged between 16 and 24 years are overweight or
obese, whereas 76% of men and 68% of women aged
between 55 and 64 years are overweight or obese [44,45].
In the USA, the prevalence of AO is 27.1, 20.2 and
21.4% in White, Black and Hispanic men, respectively.
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Fig. 1. Study design. BE, Barrett’s oesophagus; OGD, oesophagogastroduodenoscopy.
Table 1. Study inclusion and exclusion criteria
Inclusion criteriaa Exclusion criteria
Age 18–79 years Weight loss>10% in the last 12 months
Enroled in Barrett’s oesophagus endoscopic surveillance/therapeutic programme at
UCLH
Decompensated liver disease
Scheduled for OGD (indication unrelated to Barrett’s oesophagus) Inﬂammatory bowel disease
Coeliac disease
Previous upper gastrointestinal tract surgery
Known malignancy or undergoing treatment for previously resected malignancy
Inability to provide informed consent
OGD, oesophagogastroduodenoscopy; UCLH, University College Hospital, London, UK.
aLong term therapies for concomitant disease were allowed.
Table 2. Deﬁnitions used to classify patients
Deﬁnition Criteria
Obesity BMI>30 kg/m2
Overweight BMI 25–30 kg/m2
Normal weight BMI 18.5 to <25 kg/m2
Abdominal obesity WHR>0.85 in female individuals; WHR>0.90 in male individuals
Metabolic Syndrome
Deﬁned by International Diabetes Federation
criteria
Abdominal obesity plus any of the following: blood pressure≥130/85 mmHg, or receiving treatment;
triglyceride≥1.7 mmol/l, or receiving treatment; HDL cholesterol<1.03 mmol/l ♂/<1.29 mmol/l ♀, or receiving
treatment; fasting glucose TG≥1.7 mmol/l, or receiving treatment; or previous diagnosis of type 2 diabetes
Insulin resistance
Deﬁned by HOMA-IR
Fasting plasma insulin× fasting plasma glucose/405
Normal Weight Obese Syndrome in female
individuals
Body fat %>30% and BMI 18.5–25 kg/m2
HDL, high-density lipoprotein; HOMA-IR, homoeostatic model assessment-insulin resistance; TG, triglyceride; WHR, waist/hip ratio.
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The corresponding values among women are 43.2, 56.0
and 55.4% [46]. Another study in Europe shows that the
prevalence of AO is higher in women than in men (30.6 vs.
23.9%) and increases with age [47]. Stein and El-Serag
demonstrated a 15% difference between BE and controls
in the proportion of patients who were overweight or
obese [48]. There are no data available on the prevalence
of ‘metabolic’ (normal weight) obesity in the general
population.
On the basis of the current available data summarized
above, we assumed that ∼ 55% of the normal group would
have been overweight, obese, abdominally obese or
metabolically obese. A difference of 15% between the
patients and controls was chosen as clinically relevant.
With a 5% signiﬁcance level and 90% power, at least 230
participants were required in each group.
The χ2-test, Fisher’s test, Student’s t-test and logistic
analysis were used for comparison. The identiﬁed risk
factors signiﬁcantly associated with BE at univariate ana-
lysis were subsequently entered into a multivariate logistic
regression analysis.
Results
Demographics
A total of 474 patients were enroled, among whom 189
were female (F) and 285 were male (M); the mean age was
58.08 ±15.51 years. Among the 250 patients with BE, only
57 (22.8%) were female, and the mean age of the BE
patients was higher than that of controls (63.7 ±12.3 vs.
52.03 ±16.44 years; data summarized in Table 3).
Overall, 97.2% of patients and 77.2% of controls
enroled were White. BE cases were mainly tertiary referrals
from a large catchment area, whereas most controls were
referred locally from North London. On the basis of
demographic characteristics, age (cutoff: 57 years) and
male sex [M/F 193/57; odds ratio (OR) 5.01, P< 0.0001]
were identiﬁed as risk factors for BE.
Body composition
In the BE group, 99 patients (39.6%) were overweight, 80
(32%) were obese, 189 (75.6%) had AO, and, among
female individuals, 16 (28.1%) were classiﬁed as NWOS.
In the control group, 70 patients (31.3%) were over-
weight, 51 (22.8%) were obese, 115 (51.3%) had AO,
and, among the female individuals, 18.9% were classiﬁed
as NWOS (data summarized in Table 3).
When analysing the data by BMI scale for obesity,
22.8% of BE cases had a BMI between 30 and 35 and
9.2% had BMI greater than 35 (morbidity obesity). In
total, 71.6% of the cases were either overweight, obese,
AO or female individuals with NWOS, compared with
53.5% in the control group, conﬁrming our initial
hypothesis of a difference greater than 15% between
patients and controls (18.1%).
Increased BF% (F>30% and M>25%) per se was
present in 198 (79.2%) BE patients versus 143 (63.8%)
controls.
Comparison of anthropometric characteristics and
body composition showed that AO (OR 3.08, P<0.0001),
increased BF% (OR 2.29; P=0.0002) and higher BMI
(overweight OR 2.04; P< 0.001; obese OR 2.26;
P= 0.0006) were signiﬁcantly associated with BE. Our
data demonstrated a positive trend for NWOS (OR 1.69;
P= 0.1); the nonsigniﬁcance is likely because of the small
number of female patients (57 patients vs. 132 controls).
When adjusted by sex, age and race into a multivariate
analysis, the only independent risk factor associated with
BE was AO (OR 1.65; P=0.02).
Metabolic risk
Among the patients and controls, 96 and 39 (38.4 vs.
17.4%, OR= 3.00, P<0.00001) were affected by MS,
respectively. Speciﬁcally, MS was present in 39.7 versus
34.2% (OR 3.05, P<0.001), 43.7 versus 21.9% (OR 5.2,
P< 0.001), 92.1 versus 54.9% (OR 8.08, P<0.0001) of
overweight, obese, and AO patients with BE versus con-
trols, respectively (data summarized in Table 3).
History of hypertension (37.4 vs. 21.9, OR 2.3,
P< 0.0001) and dyslipidaemia (72.8 vs. 55.4, OR 2.15,
P= 0.0001) were signiﬁcantly correlated with BE, whereas
T2D and glucose intolerance (29.2 vs. 21.4, OR 1.51,
P= 0.05), but not T2D alone, were also identiﬁed as risk
factors (19.6 vs. 16.1, OR 1.22, P=NS). HbA1c was not
signiﬁcantly associated with BE, possibly because of the
use of antidiabetic drugs in this group.
Insulin levels (10.2 vs. 7.1 μIU/ml, P=0.05) and
HOMA-IR (2.54 ±2.66 vs. 1.78 ±1.82, P<0.001) were
higher in BE cases compared with controls.
A trend was observed towards decreased adiponectin
levels in BE cases versus controls, whereas leptin showed
no correlation. When the analysis was carried out by
categories for adiponectin (F<11.9, 11.9–18.6 and
≥18.7, and M<7.1, 7.1–11.3 and ≥11.4 µg/ml), the trend
remained, but was not signiﬁcant.
Intestinal metaplasia, dysplasia, cancer pathway
The association between anthropometric/body composi-
tion characteristics and changes in metabolic pathways
with the metaplasia/dysplasia pathway was analysed in the
BE group (data summarized in Table 4).
Intestinal metaplasia alone and intestinal metaplasia
with dysplasia were present in 57.2 and 42.8% of cases,
respectively. In particular, dysplasia was present in 47% of
patients with AO, 51% with MS and 58.9% with T2D. In
contrast, only 28.1% of patients without AO, 37.3% with
MS and 36.2% with T2D had BE that progressed to
dysplasia.
When analysing low-grade and high-grade dysplasia
(LGD and HGD) separately, AO was the only metabolic
parameter independently correlated with HGD alone (37.5
vs. 21%, OR 2.44, P=0.01).
Insulin levels and HOMA-IR were progressively higher
in metaplasia, low-grade dysplasia and HGD (6, 9.55 and
11.6 SCALE, respectively, for insulin levels and 2.28, 2.51
and 3 for HOMA-IR).
BMI, dyslipidaemia, BF% and hypertension were not
associated with progression to cancer, and length of BE
was not signiﬁcantly associated with any parameter of
body composition and metabolic dysfunction analysed.
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Correlation with reﬂux symptoms, hiatus hernia and
reﬂux oesophagitis
The choice of the control group was driven by the ﬁnal aim
to ensure identiﬁcation of individuals metabolically at risk
of developing BE compared with the general population,
even if experiencing reﬂux symptoms or having a diagnosis
of hiatus hernia and reﬂux oesophagitis. To validate our
hypothesis further, we carried out a subanalysis dividing
patients into BE versus reﬂux oesophagitis cases (controls:
28 patients). The presence of reﬂux symptoms and hiatus
hernia was signiﬁcantly higher in the BE group compared
with controls (66.4 vs. 25%, P=0.001 and 56.4 vs.
32.1%, P=0.002, respectively). Interestingly, MS, obesity
deﬁned by BMI, hypertension and T2D/glucose intoler-
ance were associated with BE compared with reﬂux
oesophagitis (38.4 vs. 14.3%, P= 0.01; 32 vs. 14.3%,
P=0.06; 37.4 vs. 10.7%, P= 0.001; 29.2 vs. 10.7%,
P=0.04, respectively; data summarized in Table 5).
Is Barrett’s oesophagus part of the spectrum of
metabolic syndrome?
We postulated that BE might represent a component of the
disease spectrum of MS. If BE was included as one of the
criteria to deﬁne MS, then 44% of the total enroled BE
patients in our study would be considered as affected by
MS versus 28.5% on the basis of the current deﬁnition of
Table 3. Demographics, body composition, metabolic risks and clinical characteristics in cases and controls
Barrett’s oesophagus Univariate analysis Multivariate analysis
No (n=224) Yes (n=250) OR (95% CI) P OR (95% CI) P
Age (mean ±SD) (years) 52.03 ± 16.44 63.74 ±12.37 1.05 (1.04–1.07) <0.0001
Sex [n (%)]
Female (F) 132 (58.9) 57 (22.8) NS
Male (M) 92 (41.1) 193 (77.2) 4.85 (3.26–7.20) <0.0001
Ethnicity
White 173 (77.2) 243 (97.2) NS
Black 21 (9.4) 1 (0.4) 0.03 (0.01–0.25) NS
Asian 26 (11.6) 5 (2.0) 0.14 (0.05–0.36) NS
NA 4 1 –
Hypertension
No 175 (78.1) 151 (62.6)
Yes 49 (21.9) 99 (37.4) 2.34(1.56–3.51) <0.0001
Diabetes
No 188 (83.9) 201 (80.4)
Yes 36 (16.1) 49 (19.6) 1.22 (0.76–1.97) NS
Diabetes/glucose intolerance
No 176 (78.6) 177 (70.8)
Yes 48 (21.4) 73 (29.2) 1.51 (0.99–2.30) 0.05
Hyperlipidaemia
No 100 (44.6) 68 (27.2)
Yes 124 (55.4) 182 (72.8) 2.15 (1.47–3.17) 0.0001
Abdominal obesity
No 107 (47.8) 57 (22.8)
Yes 115 (51.3) 189 (75.6) 3.08 (2.07–4.59) <0.0001 1.65 (1.07–2.56) 0.02
NA 2 4 –
Metabolic syndrome
No 183 (81.7) 150 (60.0)
Yes 39 (17.4) 96 (38.4) 3.00 (1.96–4.62) <0.0001
NA 2 4 –
BMI
Normal 101 (45.1) 70 (28.0)
Overweight 70 (31.3) 99 (39.6) 2.04 (1.32–3.14) 0.0012
Obesity 51 (22.8) 80 (32.0) 2.26 (1.42–3.60) 0.0006
NA 2 1 –
BMI for obese patients
30–35 35 (15.6) 57 (22.8) 2.34 (1.40–3.95) 0.0013
>35 16 (7.1) 23 (9.2) 2.07 (1.02–4.20) 0.04
NA 2 1 –
Body fat (BF) %
M<30, F<25% 73 (32.6) 44 (17.6)
M>30, F>25% 143 (63.8) 198 (79.2) 2.29 (1.49–3.53) 0.0002
NA 8 8
NWO syndrome
Female, normal BMI, BF>30% (n=189)
No 106 (80.3) 40 (70.2)
Yes 25 (18.9) 16 (28.1) 1.69 (0.82–3.50) NS
NA 1 1 –
Reﬂux symptoms
No 131 (58.5) 84 (33.6)
Yes 93 (41.5) 166 (66.4) 2.78 (1.91–4.04) <0.0001
Hiatus hernia
No 179 (79.9) 109 (43.6)
Yes 45 (20.1) 141 (56.4) 5.14 (3.40–7.76) <0.0001
CI, conﬁdence interval; NA, not applicable (data not collected); NS, not signiﬁcant; NOW, Normal Weight Obese; OR, odds ratio.
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MS, allowing an additional 15.5% of individuals at risk of
developing OAC to be identiﬁed.
We recognize that this speculation requires further
studies and validation; however, it might potentially have
a crucial role in the prevention of oesophageal cancer.
Discussion
We have demonstrated that body composition and the
insulin metabolic pathway, rather than obesity per se,
have a direct role in the development of BE and progres-
sion to cancer. MS, obesity, hypertension and T2D/glucose
intolerance were associated with BE compared with
reﬂux oesophagitis. Furthermore, we found that AO was
strongly associated with HGD, in addition to BE.
Finally, we demonstrated that BE was associated
with MS, dyslipidaemia, T2D/glucose intolerance and
hypertension.
Obesity represents a growing and challenging global
health problem. Adult obesity rates have nearly quad-
rupled over the last 25 years, and two-thirds of UK adults
are now overweight [44,45]. The number of obese children
has increased by 47% between 1980 and 2013 [49].
Table 4. Metabolic risk for cancer pathway and correlation with extension of Barrett’s oesophagus
Univariate analysis
Histology/extension Barrett’s oesophagus patients OR (95% CI) P
Abdominal obesity
No (n=57) [n (%)] Yes (n=189) [n (%)]
Metaplasia 41 (71.9) 100 (52.91)
LGD 4 (7.0) 18 (9.52) 1.8 (0.57–5.66)
HGD 12 (21.1) 71 (37.57) 2.44 (1.2–4.9) 0.01
Short Barrett 21 (36.8) 65 (34.4)
Long Barrett 36 (63.2) 124 (65.6) 1.12 (0.6–2.07)
Metabolic syndrome
No (n=150) [n (%)] Yes (n=96) [n (%)]
Metaplasia 94 (62.7) 47 (48.96)
LGD 14 (9.3) 8 (8.33)
HGD 42 (28.0) 41 (42.71)
Short Barrett 53 (35.3) 33 (34.4)
Long Barrett 97 (64.7) 63 (65.6)
NWO syndrome
No (n=40) [n (%)] Yes (n=16) [n (%)]
Metaplasia 30 (75.0) 8 (50.00)
LGD 0 (0.0) 2 (12.50)
HGD 10 (25.0) 6 (37.50)
Short Barrett 19 (47.5) 9 (56.3)
Long Barrett 21 (52.5) 7 (43.8)
BMI
Normal (n=70) [n (%)] Overweight (n=99) [n (%)] Obese (n=80) [n (%)]
Metaplasia 42 (60.0) 61 (61.62) 40 (50.00)
LGD 8 (11.4) 5 (5.05) 9 (11.25)
HGD 20 (28.6) 33 (33.33) 31 (38.75)
Short Barrett 24 (34.3) 36 (36.4) 27 (33.8)
Long Barrett 46 (65.7) 63 (63.6) 53 (66.3)
Diabetes/glucose intolerance
No (n=177) [n (%)] Yes (n=73) [n (%)]
Metaplasia 113 (63.8) 30 (41.10) 0.002
LGD 15 (8.5) 7 (9.59)
HGD 49 (27.7) 36 (49.32)
Short Barrett 65 (36.7) 22 (30.1)
Long Barrett 112 (63.3) 51 (69.9)
Diabetes
No (n=201) [n (%)] Yes (n=49) [n (%)]
Metaplasia 122 (60.7) 21 (42.86)
LGD 17 (8.5) 5 (10.20)
HGD 62 (30.8) 23 (46.94)
Short Barrett 76 (37.8) 11 (22.45)
Long Barrett 125 (62.2) 38 (77.55)
Hypertension
No (n=151) [n (%)] Yes (n=99) [n (%)]
Metaplasia 90 (59.6) 53 (53.54)
LGD 14 (9.3) 8 (8.08)
HGD 47 (31.1) 38 (38.38)
Short Barrett 49 (32.5) 38 (38.4)
Long Barrett 102 (67.5) 61 (61.6)
Hyperlipidaemia
No (n=68) [n (%)] Yes (n=182) [n (%)]
Metaplasia 44 (64.7) 99 (54.40)
LGD 8 (11.8) 14 (7.69)
HGD 16 (23.5) 69 (37.91)
Short Barrett 25 (36.8) 62 (34.1)
Long Barrett 43 (63.2) 120 (65.9)
HGD, high-grade dysplasia; LGD, low-grade dysplasia; NWO, Normal Weight Obese.
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Obesity contributes to up to one-third of the cancers of
the colon, breast, kidney and stomach and has also been
associated with OAC [10,11]. It is a risk factor for T2D,
heart disease, stroke, osteoarthritis, high blood pressure,
gallstones, infertility and depression and can reduce life-
span by as much as 9 years [50]. Recently, it has become
apparent that normal weight individuals with increased
adiposity, particularly visceral fat, even in the absence of
morbid obesity, are predisposed to developing MS and
perhaps other obesity-related diseases, and they are con-
sidered metabolically obese [32,33].
High prevalence of MS and central adiposity in BE has
been reported previously [18]. As BE is the strongest risk
factor for OAC, establishing a causative link is an
important public health issue because of their present
epidemic proportions, to endorse preventive strategies.
However, a direct causal link between obesity and OAC
has not been conclusively established. In part, this could be
explained by the use of BMI to stratify patients in previous
studies rather than body composition or fat distribution as
indicators of risk for obesity-associated diseases. BMI is in
fact a crude parameter that does not take into considera-
tion distribution of fat and related metabolic implications
[51,52]. Nevertheless, a meta-analysis conducted by
Kamat et al. [51] reported that increased BMI is associated
with an increased likelihood of BE. When using waist
circumference or WHR as a measure of adiposity dis-
tribution, the results were in favour of an association with
BE but not in all studies [24,43,53]. These inconsistent
data are likely due to tape-measured abdominal fat
representing both visceral and subcutaneous components;
although both exert a mechanical effect, only visceral fat
secrets adipokines and is associated with insulin resistance.
El-Serag et al. [54] evaluated the distribution of abdominal
fat components on the basis of CT scanning, demonstrat-
ing that the surface area of visceral abdominal fat was
signiﬁcantly greater in patients with BE. In a meta-analysis,
the same scientiﬁc group conﬁrmed that oesophageal
inﬂammation, metaplasia and neoplasia are associated
with central adiposity, independent of BMI [55].
A univariate analysis of the risk factors for BE, con-
ducted as part of our study, demonstrated that AO,
increased BF%, higher BMI, MS, age (>57 years) and male
sex were signiﬁcantly associated with BE. A positive trend
was demonstrated only in female individuals with NWOS.
More BE patients than controls were affected by hyper-
tension and dyslipidaemia, demonstrating that BE is
associated with MS. On multivariate analysis, the only
independent risk factor for BE was AO, which, interest-
ingly, is the only mandatory criterion that must be satisﬁed
to deﬁne MS [36].
AO, MS and T2D were signiﬁcantly associated with
dysplasia, but only AO was correlated with HGD, sug-
gesting a potential role of AO in the progression to cancer.
Ryan et al. [18] found that individuals with long-
segment BE were signiﬁcantly more obese and had higher
fasting insulin levels than those with short-segment BE,
suggesting that obesity might have a role in the extent of
BE. Conversely, in our study, the length of BE was not
signiﬁcantly associated with body fat distribution.
The aetiology of the association between BE and obesity
is under debate. It is known that an increased level of
insulin promotes carcinogenesis through its proliferative
and antiapoptotic actions and effects on the insulin growth
factor family [56–59]. In a case–control study, increased
levels of insulin and insulin-like growth factor-1 were
found to be associated with BE, supporting the hypothesis
that higher levels of these growth factors contribute to
obesity-related carcinogenesis [60]. In our study, both
insulin levels and HOMA-IR were signiﬁcantly altered in
BE, suggesting that the insulin metabolic pathway is
involved in oesophageal carcinogenesis.
There is extensive but not conclusive literature on the
relationship between adipokines and cancer. Adiponectin
is a peptide secreted by adipocytes, and its plasma levels
are inversely associated with obesity. Leptin is synthesized
in adipocytes as a 16 kDa molecule, and its circulating
level is directly proportional to the total amount of fat in
the body. Current data show that a high serum leptin level
is associated with an increased risk for BE in men but not
women, and a high level of low molecular weight adipo-
nectin is associated with a decreased risk for BE [16,32].
Mokrowieka et al. [61] did not ﬁnd signiﬁcantly higher
leptin levels in BE, but they did ﬁnd lower adiponectin
levels in BE compared with GERD patients and controls.
Deregulated leptin and adiponectin receptor expression
present in obese individuals have been correlated with
OAC, suggesting that pathways involving adipocytokines
affect tumour biology [62].
Garofalo and Surmacz [63] examined the link between
leptin and a variety of cancers including breast, colorectal,
prostate, ovarian, endometrial and lung cancer, showing
an association with cancer progression. Kelesidis et al. [64]
published a review on the association between adiponectin
and cancers including acute myelogenous leukaemia, and
breast, colorectal, prostate, endometrial and gastric can-
cers, with evidence indicating an increased cancer risk.
In our study, a trend towards decreased adiponectin
levels in BE compared with controls was observed,
whereas leptin showed no correlation. However, the three
multimeric circulating forms of adiponectin (low mole-
cular weight, middle molecular weight and high molecular
weight) were not analysed, and previous data have shown
an association only between high levels of the low mole-
cular weight form and decreased risk for BE, which might
explain the lack of correlation in our results [61,65].
The present study has some limitations. Our results
cannot be extended to different ethnicities, as the study
Table 5. Correlation with reﬂux symptoms, hiatus hernia and reﬂux
oesophagitis
Barrett’s oesophagus
[n (%)]
Reﬂux oesophagitis
[n (%)] P-value
Total patients (n) 250 28
Reﬂux symptoms 166 (66.4) 7 (25.0) 0.001
Hiatus hernia 143 (56.4) 9 (32.1) 0.002
Normal weight 70 (28) 13 (46.4) NS
Overweight 99 (39.6) 11 (39.3) NS
Obesity 80 (32.0) 4 (14.3) 0.006
AO 189 (75.6) 18 (64.3) NS
MS 96 (38.4) 4 (14.3) 0.01
T2DM+ IGT 73 (29.2) 3 (10.7) 0.04
Hypertension 99 (37.4) 3 (10.7) 0.001
Dyslipidaemia 182 (72.8) 16 (57.1) NS
AO, abdominal obesity; IGT, glucose intolerance; MS, metabolic syndrome;
NS, not signiﬁcant; T2DM, type 2 diabetes.
Obesity and metabolic pathways in Barrett’s oesophagus Di Caro et al. www.eurojgh.com 257
population included mainly Whites and it is likely that
racial differences exist. Moreover, it is not possible to
establish a temporal cause–effect link in terms of time of
onset between the analysed risk factors and BE. In addi-
tion, smoking and diet habits were not included in our
analysis: including those risk factors, however, would have
only added an imprecise estimate of their effects on our
relatively small sample size. The small number of female
individuals in the case group meant that this subgroup was
underpowered to demonstrate a deﬁnitive association
between BE and NWOS, although a trend was apparent.
Individuals with reﬂux symptoms, hiatus hernia and reﬂux
oesophagitis were included in the control group, as it
would not be economically sustainable or scientiﬁcally
justiﬁed to propose screening of all individuals in the
general population suffering from the above. In support of
this, previous case–control studies found that WHR is
associated with an increased risk for BE, independent of
BMI and GERD symptoms [24,43]. Finally, we measured
leptin and adiponectin levels in our patients but not other
cytokines, although it is well known that visceral fat is
responsible for the release of many other cytokines, such as
interleukin-1β, interleukin-6 and tumour necrosis factor-α.
It is important to recognize that the BE patients had a
disproportionately high prevalence of dysplasia, given that
all were recruited from a tertiary referral centre. We have
shown that AO, MS and T2D were more common in the
dysplasia group when compared with the nondysplastic BE
group and, therefore, it is acknowledged that all the
measured parameters are likely to be enlarged in this
cohort of BE patients when compared with controls.
Our control group included patients with reﬂux oeso-
phagitis and hiatus hernia. To identify which metabolic
risk factors were still associated with BE, we carried out a
subgroup analysis of this cohort. Interestingly MS, obesity
deﬁned by BMI, hypertension and T2D/glucose intoler-
ance were associated with BE compared with reﬂux
oesophagitis.
The association of BE with insulin resistance, MS,
dyslipidaemia and hypertension suggests the activation of
speciﬁc metabolic pathways in patients with altered BF
distribution or BMI. The intestinal metaplasia, dysplasia,
cancer pathway appears to be modulated by changes in the
metabolic pathway, in particular in MS involving a car-
cinogenic insulin pathway. Additional research and vali-
dation of BE risk factors and the association between BE
and MS are warranted to identify metabolically predis-
posed individuals in the general population who will
beneﬁt from early screening for BE, independently of the
presence of reﬂux symptoms, to prevent OAC. Patients
with GERD are more likely to be investigated endoscopi-
cally and eventually enter into a surveillance programme if
BE is diagnosed. Obese individuals who do not develop
GERD, often hidden because of the use of a proton-pump
inhibitor, will not beneﬁt from screening. Our study aimed
to identify individuals at risk for BE on the basis of
metabolic characteristics rather than presence of GERD.
Our study was designed to examine the risk of devel-
oping BE on the basis of body composition, obesity and
metabolic pathway proﬁle to identify risk factors in indi-
viduals who might beneﬁt from a screening programme for
OAC. The study, therefore, emphasizes the importance of
health promotion programmes to prevent obesity and
metabolically related diseases. The possibility that mod-
ifying behavioural risk factors for BE might be an effective
method of preventing the development of OAC should be
explored. Abdominal obesity is a strong modiﬁable beha-
vioural risk factor for BE.
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